Prostate cancer organoid demonstrating no Y loss XY paint of organoids demonstrating no Y loss.

Prostate cancer organoid demonstrating no Y loss XY paint of organoids demonstrating no Y loss.</p

Characteristics of patient-derived prostate cancer organoids.

(A) Percentage of organoids with loss of the chromosome Y (left) and Yq (right). (B) Doubling times of organoids. (C) Breakdown of organoids, stratified by type of prostate cancer tissue used for patient-derived organoid development and Y chromosome status. Chr, chromosome; CRPC, castration-resistant prostate cancer.</p

Prostate cancer organoid demonstrating partial Y loss XY paint of organoid demonstrating Y loss in some cells and no Y loss in others.

Prostate cancer organoid demonstrating partial Y loss XY paint of organoid demonstrating Y loss in some cells and no Y loss in others.</p

Characteristics of the Y chromosome in primary prostate cancer samples from patients using Mitelman’s Database.

(A) Y chromosome status in primary prostate cancer samples. (B) Y chromosome heterogeneity in primary prostate adenocarcinoma samples. Chi-square test reported significance.</p

Characteristics of patient-derived metastatic prostate cancer organoids labelled with the XY paint FISH probes.

Characteristics of patient-derived metastatic prostate cancer organoids labelled with the XY paint FISH probes.</p

Prostate cancer organoid demonstrating Y loss XY paint of organoid demonstrating complete Y loss.

Prostate cancer organoid demonstrating Y loss XY paint of organoid demonstrating complete Y loss.</p

Y chromosome paint FISH probe design and validation.

(A) FISH probe design. (B) XY paint probe validation in prostate cancer cell lines, LNCaP (left) and LAPC4 (negative control; right). Cen X, centromere X; FISH, fluorescence in situ hybridization.</p